India Pharmaceutical News

Related Pharmaceuticals Industry News

• November 2024: Helix Biopharma, a clinical-stage biopharmaceutical company focused on developing immune oncology therapies, has signed an asset purchase agreement with Laevoroc Chemotherapy AG, a private Swiss company, to acquire the Oral Gemcitabine chemotherapy compound.
• October 2024: CHEPLAPHARM Group entered into a definitive agreement with Eli Lilly and Company to acquire the worldwide rights (excluding South Korea) to Gemzar, a cancer treatment featuring the active ingredient gemcitabine. The transaction's closure was subject to standard conditions being met. Gemcitabine, a chemotherapeutic agent, was utilized in treating a spectrum of cancers, including non-small cell lung, urothelial, biliary tract, pancreatic, ovarian, cervical, and breast cancers.

• October 2024: Ixcela, the internal fitness company, in collaboration with Roper St. Francis Healthcare, reported the launch of the Ixcela Cancer Support Program. This initiative follows a landmark pilot program that demonstrates the transformative role of gut microbiome health in reducing the debilitating side.
• September 2024: EnteroBiotix, a Scottish biopharmaceutical company, received USD 21.5 million in investments from SIS Ventures and Kineticos Ventures in a series A round. The planned to use this funding advance its pipeline for multiple disease areas to enhance the gut microbiome.

• May 2024: Global prices for amlodipine besylate fell, leading to increased procurement by the pharmaceutical and healthcare sectors. The low prices resulted in increased demand for amlodipine in both national and international markets.
• October 2023: Anant Parekh, one of the study's authors, emphasized that discontinuing amlodipine as a primary treatment option could lead to a substantial increase in hypertension-related fatalities. This has increased the demand for the concerned product in the recent past and will shoe similar trends in future years.

• October 2024: Bayer's Consumer Health Division introduced Bepanthen, a skincare brand, in the Indian market. This launch highlights the company's expansion in addressing skincare needs in the country.
• August 2024: CeraVe, a leading dermatologist-recommended skincare brand in the United States announced the launch of four innovative products. These include a moisturizing lotion, SPF 50 facial lotion, gel-cream for oil control, and a vitamin C eye cream.

• March 2024: India-based Veeda Clinical Research Limited, a full-service contract research organization (CRO), acquired Heads, a full-service contract research organization that focused on conducting clinical trials in oncology. With this acquisition, Veeda enters the global CROs with integrated capabilities to extend contract research services from discovery to clinical development.
• August 2023: ECLEVAR MEDTECH, a French-based CRO specializing in medtech industry, entered a partnership with Micron, a Japanese domestic CRO, to offer services to both Japanese medtech manufacturers who want to expand their business overseas and foreign medtech manufacturers who want to enter the Japanese market.

• February 2024: IBSA UK introduced SINOVIAL, an advanced formulation targeting musculoskeletal conditions, leveraging its proprietary technology.
• March 2023: BioSenic revealed a re-evaluation of the results from its Phase III trial for JTA-004, an enhanced viscosupplement aimed at treating knee osteoarthritis (OA).

• March 2023: Coherus BioSciences received U.S. FDA approval for its pegfilgrastim-cbqv (Udencya), a pegfilgrastim biosimilar for managing febrile neutropenia induced by chemotherapy.
• September 2022: Spectrum Pharmaceuticals, Inc. received U.S. FDA approval for its ROLVEDON (eflapegrastim-xnst) injection, which is intended to decrease the incidence of infection, as manifested by febrile neutropenia in adult patients with non-myeloid-malignancies-receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

• November 2024: The Indonesian government enacted Government Regulation No. 28 of 2024, intensifying restrictions on the promotion of infant formula products. This regulation included prohibitions on discounts, indirect promotions, and endorsements by social media influencers, aiming to reduce marketing activities within the sector.
• March 2024: Indofood CBP Sukses Makmur launched Promina Rice Crackers, targeting the burgeoning baby finger food market in Indonesia. The product, developed in partnership with Fujian Tongcheng Food Group, aimed to cater to health-conscious parents seeking nutritious snack options for infants.

• December 2024: Cosibelimab, a novel therapeutic targeting advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer, has received approval from the United States Food and Drug Administration (FDA). This marks the first PD-L1 (Programmed Death-Ligand 1) inhibitor authorized for use in adults with CSCC that has metastasized or is unsuitable for surgical or radiation intervention.
• February 2024: Quest Diagnostics has introduced MelaNodal Predict, an advanced gene expression test aimed at supporting personalized treatment strategies for melanoma patients. As melanoma remains the most fatal form of skin cancer and one of the most frequently diagnosed cancers in the United States, this innovation addresses a critical need.

• May 2024: Pfizer Hospital launched Carboprost Tromethamine Injection, USP 250 mcg/mL Single Dose Vial, to its portfolio in the United States. Carboprost is one of the popular drugs to cause abortion.
• July 2023: Endo International plc and Premier, Inc. announced that Endo's Par Sterile Products division had agreed to supply Pitocin (oxytocin injection, USP) vials through Premier's ProvideGx and PremierProRx programs. Pitocin is used to induce labor in pregnant women.